Cancer vaccine - Acuvax
Alternative Names: p53 cancer vaccine - Avantogen; Pentrix; Pentrys; Pentrys prostate vaccine - Avantogen; Prostate cancer vaccine - AvantogenLatest Information Update: 31 Dec 2021
At a glance
- Originator Avantogen
- Developer Acuvax
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 28 Apr 2006 This vaccine is still in active development
- 30 May 2005 Australian Cancer Technology is now called Avantogen
- 23 Mar 2005 Australian Cancer Technology has completed enrolment in a phase IIb trial for hormone-refractory prostate cancer in Australia